Characterization of the response to treatment with ANTI-D immunoglobulin in patients with primary immune thrombocytopenia in a high complexity Colombian health center

Caracterización de la respuesta al tratamiento con inmunoglobulina ANTI-D en pacientes con trombocitopenia inmune primaria en un centro de salud colombiano de alta complejidad

Published 2025-11-30

Open | Download
PDF (Spanish) FLIP

How to Cite

1.
Serna Trejos JS, Castro Galvis CA, Bermúdez Moyano SG, Rodríguez Fonseca LC, Diaz Beltrán JC, Mantilla Melo DA, et al. Characterization of the response to treatment with ANTI-D immunoglobulin in patients with primary immune thrombocytopenia in a high complexity Colombian health center. Rev. colomb. hematol. oncol. [Internet]. 2025 Nov. 30 [cited 2025 Dec. 5];12(2):26-39. https://doi.org/10.51643/22562915.748

Download Citation

Citations
Crossref
Citations in Crossref
Scopus
Citations in Scopus
Google Scholar
Google Sholar Citation
Europe PMC
Issue
Vol. 12 No. 2 (2025): Julio-diciembre
Section
Original articles
How to Cite
1.
Serna Trejos JS, Castro Galvis CA, Bermúdez Moyano SG, Rodríguez Fonseca LC, Diaz Beltrán JC, Mantilla Melo DA, et al. Characterization of the response to treatment with ANTI-D immunoglobulin in patients with primary immune thrombocytopenia in a high complexity Colombian health center. Rev. colomb. hematol. oncol. [Internet]. 2025 Nov. 30 [cited 2025 Dec. 5];12(2):26-39. https://doi.org/10.51643/22562915.748
DOI

https://doi.org/10.51643/22562915.748
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Juan Santiago Serna Trejos
Icesi University image/svg+xml
Roles:  
https://orcid.org/0000-0002-3140-8995
Carlos Andrés Castro Galvis
Pontifical Xavierian University image/svg+xml
Roles:  
https://orcid.org/0000-0002-8314-4506
Stefanya Geraldine Bermúdez Moyano
Hospital Universitario del Valle ESE image/svg+xml
Roles:  
https://orcid.org/0000-0002-2259-6517
Laura Catalina Rodríguez Fonseca
Hospital Universitario del Valle ESE image/svg+xml
Roles:  
https://orcid.org/0009-0002-9194-632X
Juan Camilo Diaz Beltrán
Clínica Imbanaco, Cali, Colombia.
Roles:  
https://orcid.org/0009-0002-6304-1718
Show authors biography

Juan Santiago Serna Trejos,

MD, MSc, PhD (c), residente de Medicina Interna.  Departamento de Medicina Interna, Universidad ICESI, Cali, Colombia.

Carlos Andrés Castro Galvis,

Médico, residente de Medicina de Urgencias. Departamento de Medicina de Urgencias, Pontificia Universidad Javeriana, Cali, Colombia. 

Stefanya Geraldine Bermúdez Moyano,

Médica. Departamento de Medicina Crítica y Cuidado Intensivo, Hospital Universitario del Valle, Cali, Colombia

Laura Catalina Rodríguez Fonseca,

Médica, residente de Radiología. Departamento de Radiología e Imágenes Diagnosticas, Hospital Universitario del Valle, Cali, Colombia.

Juan Camilo Diaz Beltrán,

Médico UCI. Departamento de Medicina Crítica y Cuidado Intensivo, Clínica Imbanaco, Cali, Colombia.

Daniela Alejandra Mantilla Melo,

Médica. Departamento de Medicina de Urgencias, Clínica San Rafael, Pereira, Colombia.

Juan Camilo Ángel Medina,

Médico. Departamento de Medicina Critica y Cuidado Intensivo, Hospital Universitario del Valle, Cali, Colombia. 

David Altman Salcedo,

Médico. Departamento de Medicina Critica y Cuidado Intensivo, Hospital Universitario del Valle, Cali, Colombia.

Introduction: Primary immune thrombocytopenia (PIT) is an autoimmune disorder characterized by platelet destruction and reduced platelet production. Anti-D immunoglobulin (Anti-D Ig) is a less expensive therapeutic option, but its efficacy in the local population is not well studied. Objective: To describe the clinical and paraclinical response to treatment with intravenous Anti-D Ig (50 µg/kg) in Rh+ patients with TIP. Methods: Retrospective cohort study in 25 patients treated between 2020-2022 in a hematology center in Colombia. Sociodemographic, clinical and paraclinical variables were analyzed. Response was defined as a platelet count (PR) >30,000/µL or an increase ≥2 times the baseline value. Results: 80% responded to treatment, with a median post-treatment PR of 94,000/µL at 1 year. Most (70%) required 2-4 doses. Skin and mucosal hemorrhagic manifestations decreased significantly. Hemoglobin drop was mild in 33.3%. Mild adverse effects such as asthenia (20.8%) and osteomioarthralgias (4.2%) were reported. Conclusion: Treatment with Ig Anti-D showed high efficacy and tolerance in patients who did not respond to steroids, with a favorable safety profile and results superior to those reported internationally. Its use may be a viable option in this population.

Article visits 72 | PDF visits 17

Downloads

Download data is not yet available.
  1. Vizcaíno G. Tratamiento de la púrpura trom¬bocitopénica inmune crónica. Buscando algo mejor. Revisión. Invest Clin [Internet]. 2009;50(1):1-11. Disponible en: https://produccioncientificaluz.org/index.php/investigacion/article/view/28730
  2. Bylsma LC, Fryzek JP, Cetin K, Callaghan F, Bezold C, Mehta B, et al. Systematic litera¬ture review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol [Internet]. 2019;94(1):118-32. Disponible en: https://doi.org/10.1002/ajh.25301 DOI: https://doi.org/10.1002/ajh.25301
  3. Donga PZ, Bilir SP, Little G, Babinchak T, Munakata J. Comparative treatment-re¬lated adverse event cost burden in immune thrombocytopenic purpura. J Med Econ [Internet]. 2017;20(11):1200-6. Disponible en: https://doi.org/10.1080/13696998.2017.1370 425 DOI: https://doi.org/10.1080/13696998.2017.1370425
  4. Provan D, Newland AC. Current Manage¬ment of Primary Immune Thrombocyto¬penia. Adv Ther [Internet]. 2015;32(10):875- 87. Disponible en: https://doi.org/10.1007/s12325-015-0251-z DOI: https://doi.org/10.1007/s12325-015-0251-z
  5. Abdelmahmuod EA, Ali E, Ahmed MA, Yassin MA. Eltrombopag and its beneficial role in management of ulcerative Colitis associated with ITP as an upfront therapy case report. Clin Case Reports [Internet]. 2021;9(3):1416-9. Disponible en: https://doi.org/10.1002/ccr3.3783 DOI: https://doi.org/10.1002/ccr3.3783
  6. Nomura S. Advances in diagnosis and treat¬ments for immune thrombocytopenia. Clin Med Insights Blood Disord [Internet]. 2016;9:15-22. Disponible en: https://doi.org/10.4137/CMBD.S39643 DOI: https://doi.org/10.4137/CMBD.S39643
  7. Puavilai T, Thadanipon K, Rattanasiri S, Ingsathit A, McEvoy M, Attia J, et al. Treat¬ment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol [Internet]. 2020;188(3):450-9. Disponible en: https://doi.org/10.1111/bjh.16161 DOI: https://doi.org/10.1111/bjh.16161
  8. Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, et al. Romiplostim and Eltrombopag in Immune Thrombocyto¬penia as a Second-Line Treatment. Cureus [Internet]. 2020;1-2. Disponible en: https://doi.org/10.7759/cureus.9920 DOI: https://doi.org/10.7759/cureus.9920
  9. Provan D. Updated international consensus report on the investigation and manage¬ment of primary immune thrombocyto¬penia. Blood [Internet]. 2019;26(22):3780. Disponible en: https://doi.org/10.1542/peds.2020-1419 DOI: https://doi.org/10.1182/bloodadvances.2019000812
  10. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for manage¬ment of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet [Internet]. 2011;377(9763):393- 402. Disponible en: https://doi.org/10.1016/S0140-6736(10)60959-2 DOI: https://doi.org/10.1016/S0140-6736(10)60959-2
  11. Bhattacharjee S, Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med [Internet]. 2020;2(11):2048-58. Disponible en: https://doi.org/10.1007/s42399-020-00521-8 DOI: https://doi.org/10.1007/s42399-020-00521-8
  12. Tărniceriu CC, Hurjui LL, Florea ID, Hurjui I, Gradinaru I, Tanase DM, et al. Immune Thrombocytopenic Purpura as a Hemor¬rhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms. Med [Internet]. 2022;58(2):1-2. Disponible en: https://doi.org/10.3390/medicina58020211 DOI: https://doi.org/10.3390/medicina58020211
  13. Perera M, Garrido T. Advances in the patho¬physiology of primary immune thrombocyto¬penia. Hematology [Internet]. 2017;22(1):41- 53. Disponible en: https://doi.org/10.1080/10245332.2016.1219497 DOI: https://doi.org/10.1080/10245332.2016.1219497
  14. Montaño JA, Cuéllar F, Maya LM et al. Púrpura trombocitopénica autoinmune crónica en adultos. Análisis de 80 paci-entes observados durante una década. Acta Médica Colomb [Internet]. 1992;17(4):221-8. Disponible en: https://www.actamedicaco¬lombiana.com/ojs/index.php/actamed/article/view/4221/3333
  15. González-López TJ, Alperovich G, Burillo E, Espejo-Saavedra Soler M, Rebollo-Gómez E, Hernández I, et al. Epidemiology, Treat¬ment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study. TH Open [Internet]. 2024;08(03):e252-65. Disponible en: https://doi.org/10.1055/a-2336-1062 DOI: https://doi.org/10.1055/a-2336-1062
  16. Bavunoğlu I, Eşkazan AE, Ar MC, Cengiz M, Yavuzer S, Salihoğlu A, et al. Treatment of patients with immune thrombocyto¬penia admitted to the emergency room. Int J Hematol [Internet]. 2016;104(2):216- 22. Disponible en: https://doi.org/10.1007/s12185-016-2003-5 DOI: https://doi.org/10.1007/s12185-016-2003-5
  17. Waghmare B V, Jajoo S. Navigating Primary Immune Thrombocytopenia During Preg¬nancy: Management Strategies and Consid¬erations: A Comprehensive Review. Cureus [Internet]. 2024;1-2. Disponible en: https://doi.org/10.7759/cureus.67284 DOI: https://doi.org/10.7759/cureus.67284
  18. Witkowski M, Witkowska M, Robak T. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. Eur J Haematol [Internet]. 2019;103(6):531-41. Disponible en: https://doi.org/10.1111/ejh.13319 DOI: https://doi.org/10.1111/ejh.13319
  19. Xiao Q, Lin B, Wang H, Zhan W, Chen P. The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Anal¬ysis. Front Med [Internet]. 2021;8:1-2. Disponible en: https://doi.org/10.3389/fmed.2021.656792
  20. Pishko AM, Misgav M, Cuker A, Cines DB, George JN, Vesely SK, et al. Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematolo¬gist–oncologists. J Thromb Thrombolysis [Internet]. 2018;46(1):24-30. Disponible en: https://doi.org/10.1007/s11239-018-1649-7 DOI: https://doi.org/10.1007/s11239-018-1649-7
  21. Liu X, Bai X, Chen F, et al. Chinese guide¬lines for treatment of adult primary immune thrombocytopenia. Int J Hematol [Internet]. 2018;107(6):615-23. Disponible en: https://doi.org/10.1007/s12185-018-2445-z DOI: https://doi.org/10.1007/s12185-018-2445-z
  22. Martínez-Carballeira D, Bernardo Á, Caro A, Soto I, Gutiérrez L. Treatment of Immune Thrombocytopenia: Contextu-alization from a Historical Perspective. Hematol Rep [Internet]. 2024;16(3):390- 412. Disponible en: https://doi.org/10.3390/hematolrep16030039 DOI: https://doi.org/10.3390/hematolrep16030039
  23. Manasa K, Soumya R, Vani R. Phytochemicals as potential therapeutics for thrombocyto¬penia. J Thromb Thrombolysis [Internet]. 2016;41(3):436-40. Disponible en: https://doi.org/10.1007/s11239-015-1257-8 DOI: https://doi.org/10.1007/s11239-015-1257-8
  24. Fleishaker DL, Mukherjee A, Whaley FS, Daniel S, Zeiher BG. Safety and pharmaco¬dynamic dose response of short-term pred¬nisone in healthy adult subjects: A dose ranging, randomized, placebo-controlled, crossover study. BMC Musculoskelet Disord [Internet]. 2016;17(1):1-2. Disponible en: https://doi.org/10.1186/s12891-016-1135-3 DOI: https://doi.org/10.1186/s12891-016-1135-3
  25. Mititelu A, Onisâi MC, Roșca A, Vlădăreanu AM. Current Understanding of Immune Thrombocytopenia: A Review of Pathogen¬esis and Treatment Options. Int J Mol Sci [Internet]. 2024;25(4):1-2. Disponible en: https://doi.org/10.3390/ijms25042163 DOI: https://doi.org/10.3390/ijms25042163
  26. Lakhwani S, López-Las Heras A, Rodrí¬guez-García P, Iraheta S, Martín-Santos T, Rodríguez-Salazar MJ, et al. Intramuscular Anti-D treatment for immune thrombocy¬topenia: A single centre experience. Br J Haematol [Internet]. 2023;200(3):353-7. Disponible en: https://doi.org/10.1111/bjh.18484 DOI: https://doi.org/10.1111/bjh.18484
  27. Thapa Chhetri S, Kunwor B, Sharma B, Joshi P, Timilsina S. Immune Thrombocy¬topenic Purpura in an Adult Male: A Case Report. Cureus [Internet]. 2023;37942396. Disponible en: https://doi.org/10.7759/cureus.46664 DOI: https://doi.org/10.7759/cureus.46664
  28. Naithani R, Kumar R, Mahapatra M, Tyagi S, Saxena R. Efficacy and safety of anti-D for treatment of adults with immune thrombo¬cytopenia. Platelets. 2009;20(7):525-7. DOI: https://doi.org/10.3109/09537100903144617
  29. Longhurst HJ, O’Grady C, Evans G, De Lord C, Hughes A, Cavenagh J, et al. Anti-D immunoglobulin treatment for thrombo¬cytopenia associated with primary anti¬body deficiency. J Clin Pathol [Internet]. 2002;55(1):64-6. Disponible en: https://doi.org/10.1136/jcp.55.1.64 DOI: https://doi.org/10.1136/jcp.55.1.64
  30. Rodeghiero F. First-line therapies for immune thrombocytopenic purpura: Re-evalu¬ating the need to treat. Eur J Haematol [Internet]. 2008;80(SUPPL. 69):19-26. Disponible en: https://doi.org/10.1111/j.1600-0609.2007.01000.x DOI: https://doi.org/10.1111/j.1600-0609.2007.01000.x
  31. Xiao Q, Lin B, Wang H, Zhan W, Chen P. The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Anal¬ysis. Front Med [Internet]. 2021;8(May). Disponible en: https://doi.org/10.3389/fmed.2021.656792 DOI: https://doi.org/10.3389/fmed.2021.656792
  32. Mishra K, Kumar S, Singh K, Jandial A, Sandal R, Kant K. Real world experience of anti D immunoglobulin in immune throm¬bocytopenia. Ann Hematol [Internet]. 2022;101:1173-9. Disponible en: https://doi.org/10.1007/s00277-022-04829-4 DOI: https://doi.org/10.1007/s00277-022-04829-4
Tutorials

Autors:

How send article?

Evaluator pair

How to evaluate an article?

Information

Directories and Indexers


Plagiarism Check

Logo 1
Descriptor

Logo 2
Google Scholar profile

QR code

Keywords

Most read in the last 30 days

Current Issue

Sistema OJS 3.4.0.7 - Metabiblioteca |